Sign in

CIK 0001746473

  • Non-accelerated filer
  • Smaller reporting company

PLIANT THERAPEUTICS, INC.

Sign in to watch
Ticker
PLRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
474272481
Phone
+1 650-481-6770
Business address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Planned sale General Counsel & Corp. Sec'y sold 7,751 shares at an average $26.62 ($206,329)
  4. 4 Planned sale Chief Medical Officer sold 11,245 shares at $26.52 ($298,228)
  5. 4 Planned sale Chief Business Officer sold 9,036 shares at $26.52 ($239,643)
  6. 4 Planned sale Chief Financial Officer sold 9,960 shares at $26.52 ($264,148)
  7. 4 Planned sale President and CEO sold 35,339 shares at $26.52 ($937,222)
  8. 4 Grant or award General Counsel & Corp. Sec'y acquired 13,593 shares (grant or award)
  9. 4 Grant or award Chief Medical Officer acquired 21,874 shares (grant or award)
  10. 4 Grant or award Chief Business Officer acquired 17,578 shares (grant or award)
  11. 4 Grant or award Chief Financial Officer acquired 19,375 shares (grant or award)
  12. 4 Grant or award President and CEO acquired 68,749 shares (grant or award)
  13. 4 Derivatives Options or other derivatives
  14. 3 Insider Initial Statement of Ownership
  15. 4 Derivatives Options or other derivatives
  16. 3 Insider Initial Statement of Ownership
  17. 4 Open-market sale President and CEO sold 30,000 shares at an average $33.91 ($1,017,430)
  18. 4 Open-market sale President and CEO sold 45,000 shares at an average $34.48 ($1,551,637)
  19. 4 Grant or award Chief Financial Officer acquired 54,000 shares (grant or award)
  20. 4 Grant or award Chief Business Officer acquired 54,000 shares (grant or award)

Page 6 of 11 · 215 filings